Skip to main content

Restless legs affect many people with MS, review finds

By MS Buddy ·

Summarized from JAMA, Jan 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Review · people with restless legs syndrome, including people with MS

Research by John Winkelman and Benjamin Wipper at Brigham and Women's Hospital.

How common is restless legs syndrome in people with MS?

Key Takeaway

A review found that restless legs syndrome is common in people with MS and can disrupt sleep.

Cut-paper legs shift beneath a rumpled blanket in a quiet, moonlit bedroom.
Credibility
Interest
Share:1 min read

What They Found

Restless legs syndrome causes a strong urge to move, usually in the legs. Unpleasant feelings, such as aching or tingling, often come with it. Symptoms tend to worsen while resting and improve during movement, especially in the evening or at night. The review reported restless legs syndrome in about 28% of people with MS. Across the studies reviewed, about 70% of people taking certain nerve-pain medicines reported major improvement, compared with about 40% taking a placebo (an inactive treatment).

Who Should Care and Why

This review covers people with restless legs syndrome, including people with MS. Its findings about treatments are not specific to people with MS. Restless legs symptoms can make it hard to fall asleep or stay asleep. The review also describes how doctors identify the condition from a person's symptoms. It reports that some medicines used for restless legs can make symptoms worse over time.

Important Considerations

You should know this is a review, not a new study testing a treatment in people with MS. The abstract does not give a total number of people included in the studies it reviewed. You cannot tell from this abstract whether the reported treatment results apply equally to people with MS.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in JAMA by . Reproduced from the PubMed record.

Restless legs syndrome (RLS) is a sleep-related movement disorder that affects approximately 3% of US adults to a clinically significant extent and can cause substantial sleep disturbance. Restless legs syndrome is characterized by an overwhelming urge to move the limbs, typically the legs, often accompanied by unpleasant limb sensations (eg, achiness, tingling). Symptoms, provoked by immobility, are relieved while moving and are typically present or most severe in the evening or at night. Restless legs syndrome symptoms may lead to difficulty falling asleep, staying asleep, or returning to sleep. According to population-based studies, approximately 8% of US adults experience RLS symptoms of any frequency annually and 3% experience moderately or severely distressing symptoms at least twice weekly. Patients with RLS have impaired quality of life and elevated rates of cardiovascular disease (29.6% with coronary artery disease, stroke, or heart failure), depression (30.4%), and suicidal ideation or self-harm (0.35 cases/1000 person-years). Restless legs syndrome is common among patients with multiple sclerosis (27.5%), end-stage kidney disease (24%), and iron deficiency anemia (23.9%); during pregnancy and especially in the third trimester (22%); with peripheral neuropathy (eg, diabetic, idiopathic; 21.5%); and with Parkinson disease (20%). Other risk factors include family history of RLS, northern European descent, female sex (2:1 vs male sex), and older age (RLS prevalence of 10% in adults ≥65 years). Restless legs syndrome is diagnosed based on clinical history; polysomnography is not recommended for diagnosis. Iron supplementation with ferrous sulfate (325-650 mg daily or every other day) or intravenous iron (1000 mg) should be initiated for serum ferritin level less than or equal to 100 ng/mL or transferrin saturation less than 20%. If possible, medications associated with RLS, including serotonergic antidepressants, dopamine antagonists, and centrally acting H1 antihistamines (eg, diphenhydramine), should be discontinued. Gabapentinoids (eg, gabapentin, gabapentin enacarbil, pregabalin) are first-line pharmacologic therapy. In randomized clinical trials, approximately 70% of patients treated with gabapentinoids had much or very much improved RLS symptoms vs approximately 40% with placebo (P < .001). Dopamine agonists (eg, ropinirole, pramipexole, rotigotine) are no longer recommended as first-line medications due to the risk of augmentation, an iatrogenic worsening of RLS symptoms, which has an annual incidence of 7% to 10% with these medications. Patients who do not improve with first-line treatment or have augmented RLS often benefit from low-dose opioids (eg, methadone 5-10 mg daily). Restless legs syndrome affects approximately 3% of adults and can have negative effects on sleep and quality of life. Initial management includes cessation of exacerbating medications, as well as iron supplementation for patients with low-normal iron indices. If medication therapy is indicated, gabapentinoids are first-line treatment.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two paper stepping-stone paths, one more evenly spaced beside a Pilates mat and blank speech bubbles.
Adding talk therapy to Pilates improved walking in MS

11/20/2026

In a trial of 90 adults with MS, adding fatigue-focused talk therapy to supervised Pilates improved

Read More
Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Two abstract networks of curved blue and clay paths form different connection patterns on an off-white background.
Brain connection changes linked to thinking in early MS

11/20/2026

A small study followed brain connections and thinking in early MS over 10 months. Patterns differed

Read More
Matching walking shoes side by side, one on a home rug and one on an exercise mat, in navy and ochre.
Home exercise matched facility exercise for MS walking

11/19/2026

In a study of 379 people with MS and walking difficulties, home and facility exercise had similar wa

Read More
Six overlapping paper window frames reveal slightly different views of the same muted blue and sage landscape.
MS fatigue questionnaires can give different results

11/19/2026

Six fatigue questionnaires gave similar group results in MS, but individual scores differed for up t

Read More
A winding blue paper path curves around ochre shapes toward a resting circle bordered by an incomplete paper ring.
MS fatigue may reflect extra effort to control movement

11/17/2026

A review suggests MS fatigue may reflect extra effort to control movement and incomplete recovery af

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.